AliquantumRx Inc. announced today the execution of a new collaborative research agreement with The Johns Hopkins University to advance the development of cethromycin hydrochloride (Cethromycin HCl) for the treatment and prevention of liver-stage malaria.
Under the agreement, investigators from Johns Hopkins and AliquantumRx will collaborate on translational and preclinical research activities supporting the continued development of Cethromycin HCl, including studies related to mechanism of action, resistance, and data generation to inform regulatory submissions, and a Phase I/IIa clinical trials. The collaboration builds on a long-standing scientific relationship between the parties and prior discoveries demonstrating cethromycin’s activity against liver-stage malaria parasites.
The research will be led at Johns Hopkins by Dr. David Sullivan, Professor at the Bloomberg School of Public Health, and at AliquantumRx by Dr. Nikola Kaludov, President and Co-Founder.
“This collaboration formalizes and extends a productive scientific partnership going on since 2011 focused on addressing one of the most persistent challenges in malaria treatment—eliminating dormant liver-stage infection,” said Dr. Sullivan. “By combining academic discovery with translational development, we aim to generate data that can meaningfully advance this program.”
“This agreement reflects the continued alignment between AliquantumRx and Johns Hopkins around the development of Cethromycin HCl as a potential next-generation therapy for malaria,” said Dr. Kaludov. “We value the depth of expertise at Johns Hopkins and look forward to advancing this work together.”
The collaborative research is intended to support ongoing IND-enabling activities and early clinical development planning for Cethromycin HCl.
About AliquantumRx Inc.
AliquantumRx is a near-clinical infectious-disease company developing Cethromycin HCl, a G6PD-independent, short-course therapy designed to eliminate dormant liver-stage malaria and prevent relapse.
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements subject to risks and uncertainties, including those related to research outcomes, regulatory interactions, and clinical development timelines. Actual results may differ materially. AliquantumRx assumes no obligation to update these statements.